Health TrialsbyHealthPanel

Development, Standardisation and Standardisation Project for a New Memory Assessment

ConditionMemory Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorUniversity Hospital, Tours

About this trial

Episodic memory (EM) is a neuropsychological marker of Alzheimer's disease (AD) (Thomas-Anterion, 2006). Current tests for its assessment do not take into account the identity and emotional aspects of memory (Van der Linden et al., 2018). However, there are models that integrate links with identity, self-awareness and experience. Pause et al. (2013) propose criteria to create ecological tools, including consideration of the emotional valence of memories and the spatio-temporal context of acquisition. In line with these criteria, we have developed a new tool: the NEM (New evaluation of Episodic Memory). Preliminary studies show different response profiles on the NEM among patients (Launay et al., 2023). We now want to evaluate the relevance of this tool in the differential diagnosis of AD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 50 years

Ability to understand judged sufficient by the assessor;

Amnesic MCI profile (Petersen, 2003) during the 1st medical consultation prior to the assessment being prescribed.

Disqualifiers

Severe auditory and/or visual sensory impairment not compatible with neuropsychological assessment;

Judged fit to take the test by the assessor;

Patient under guardianship, curatorship or family guardianship;

Opposition to data processing.

Trial population

Patient attending a memory consultation for suspected Alzheimer's disease.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • New memory assessment

    Other intervention

    The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: group intervention1 intervention

Trial outcomes

Primary outcomes

1

Score total NEM (new memory assessment)

Sum of the episodic elements

Time frame
baseline

Secondary outcomes

1

NEM sub-scores

Sum of the episodic elements by category

Time frame
baseline
2

Total RL/RI 16 Recall

(Van der Linden et al., 2014)

Time frame
baseline
3

Delayed Mem Logic Recall

(MEM IV, Wechsler, 2014)

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Tours

Lead sponsor

Source ClinicalTrials.gov
Apply now